Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase l, Open-label, First in Human, Feasibility and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

Next Previous
Trial Profile

A Phase l, Open-label, First in Human, Feasibility and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NSI 566 (Primary) ; NSI 566 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions; First in man
  • Sponsors Neuralstem; Seneca Biopharma

Most Recent Events

  • 03 May 2018 According to a Neuralstem media release, results of post-hoc comparison of combined cohorts from Phase 1 and 2 trials vs. historical controls were published in the Annals of Clinical and Translational Neurology.
  • 27 Jan 2016 According to a Neuralstem media release, data from this study was presented at the Phacilitate Cell & Gene Therapy World Conference, Washington D.C.
  • 29 Sep 2015 Results presented for 9 month phase II and combined phase I and phase II data presented at the American Neurological Association Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top